HershJ Posted - 1 week ago

$ANIP this is going to get bought out

Dy2ski Posted - 2 weeks ago

$ANIP Good C/C. Management continues to execute and producing significant growth and even raising Full Year Guidance yet again... they definitely deserve credit! Well done! The manufacturing issues between $EYPT, Alimera and the FDA were well known so still puzzling how it was still an issue at Closing of the deal. Would be borderline Criminal on Alimera's part if they didn't notify $ANIP during the sales process (doubtful), even if $ANIP management or a 3rd party missed it on the Due Diligence processes. In any case, appreciate CEO Lalwani fully answering the Analysts question pertaining to the matter and appreciate the color he gave and as of now, it's looking like a very nice, bolt- on acquisition for the company and symbiotic to their Sales Force. Look forward to upcoming conferences for more from management.

d_risk Posted - 2 weeks ago

$ANIP - 10Q - Updated Risk Factors New risks post-Alimera acquisition: reliance on third-party manufacturers, integration challenges, increased international operations, and substantial debt. Potential impacts on stock price and financial health if benefits aren't realized. https://d-risk.ai/ANIP/10-Q/2024-11-08

DonCorleone77 Posted - 2 weeks ago

$ANIP ANI Pharmaceuticals reports Q3 adjusted EPS $1.34, consensus $1.09 Reports Q3 revenue $148.3M, consensus $144.35M. "I am very pleased to report our third quarter results as we continue to execute against our purpose of 'Serving Patients, Improving Lives,'" said Nikhil Lalwani, President & CEO of ANI. "During the quarter, our team drove record performance for both our lead Rare Disease asset Cortrophin Gel and our Generics business. We also put a new, more efficient and effective capital structure in place and completed the acquisition of Alimera, which is highly synergistic to our Rare Disease business. We believe our proven commercial execution capabilities can further unlock the potential for ILUVIEN and YUTIQ, two growing and durable assets, as well as accelerate the growth of Cortrophin Gel in ophthalmology. Based on our strong third quarter results, the continued momentum across the business, and the addition of ILUVIEN and YUTIQ, we are pleased to raise our full year 2024 guidance," concluded Lalwani.

ldyofsrrw Posted - 2 weeks ago

$ANIP watching this one super close

Dy2ski Posted - 2 weeks ago

$ANIP Earnings CC this week. Management PR'd the call after hours...and scheduled it for a Friday... and they've been relatively quiet for months other than the botched Alimera deal... but we shall see, if the market is wrong and stock's weakness reverses.

Estimize Posted - 10/28/24

Wall St is expecting 9.24% YoY revenue growth for $ANIP in Q3, down from 18.44% in Q2 [Reporting 11/06 BMO] http://www.estimize.com/intro/a

prismmarketview Posted - 10/25/24

$ANIP https://prismmarketview.com/ani-pharmaceuticals-launches-fda-approved-estradiol-gel-0-06/

OpenOutcrier Posted - 10/25/24

$ANIP (+4.1% pre) ANI Pharmaceuticals introduces generic Estradiol Gel - inv https://ooc.bz/l/45767

DonCorleone77 Posted - 10/25/24

$ANIP ANI Pharmaceuticals announces FDA approval of Estradiol Gel, 0.06% ANI Pharmaceuticals announced that following final approval from the U.S. FDA for its Abbreviated New Drug Application, the company launched Estradiol Gel, 0.06%. ANI's Estradiol Gel, 0.06% is the generic version of the reference listed drug EstroGel Gel, 0.06%. U.S. annual sales for Estradiol Gel, 0.06% total approximately $16.7M, based on August 2024 moving annual total (MAT) IQVIA data.

themacromindset Posted - 10/24/24

$ANIP ANI Pharmaceuticals to Present New Data Highlighting Membranous Nephropathy Research at American Society of Nephrology Kidney Week 2024

WeeklyTrader Posted - 1 month ago

Who's ready to capitalize on $ANIP? RSI: 54.86% 50-day MA: $59.41 200-day MA: $61.9

swingingtech Posted - 1 month ago

$MGTX $ANIP $ALNY $FOLD https://wallstreetwaves.com/mgtx-stock-rises-following-positive-results-from-parkinsons-disease-trial/

WeeklyTrader Posted - 1 month ago

Let’s cheer for $ANIP and watch it soar! RSI: 50.71% 50-day MA: $59.32 200-day MA: $61.79

swingingtech Posted - 1 month ago

$ANIP https://wallstreetwaves.com/piper-sandler-initiates-coverage-of-ani-pharmaceuticals-anip-with-overweight-recommendation/

Thestocktraderhubzee Posted - 1 month ago

WATCHLIST OCT 11 2024 $AMZN Pivotal Research Initiates Coverage On Amazon.com with Buy Rating, Announces Price Target of $260 $ANIP Piper Sandler Initiates Coverage On ANI Pharmaceuticals with Overweight Rating, Announces Price Target of $68 $GE Citigroup Maintains Buy on GE Aero, Raises Price Target to $216 $MPC Citigroup Maintains Neutral on Marathon Petroleum, Lowers Price Target to $167 $BWIN JP Morgan Maintains Overweight on Baldwin Insurance, Raises Price Target to $54

CashFlowBurnrate Posted - 1 month ago

$ANIP whats up with pre market ?

DonCorleone77 Posted - 09/26/24

$ANIP ANI Pharmaceuticals announces FDA approval, launch of Ketoconazole Shampoo, 2% ANI Pharmaceuticals announced that following final approval from the U.S. FDA for its Abbreviated New Drug Application, the company launched Ketoconazole Shampoo, 2%. ANI's Ketoconazole Shampoo, 2% is the generic version of the reference listed drug Nizoral. U.S. annual sales for Ketoconazole Shampoo, 2% total approximately $69.2M, based on July 2024 moving annual total IQVIA data.

themacromindset Posted - 09/26/24

$ANIP $ANIP ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2%

Stock_Titan Posted - 09/26/24

$ANIP ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2% https://www.stocktitan.net/news/ANIP/ani-pharmaceuticals-announces-the-fda-approval-and-launch-of-im2qcw93xd1w.html

Himel92 Posted - 2 months ago

The Last month Performance for $ANIP Opening Price: $60.17 Closing Price: $56.20 Highest Price: $64.21 Lowest Price: $52.53 Percentage Change: -6.60% Data analyst: AITX

Dy2ski Posted - 2 months ago

$ANIP Pretty extensive PR this morning outlining the company's belief in future growth and great to see another new record for Cortrophin patient starts for August. As far as the Alimera transaction closing...any positive feelings of possible accretiveness with the purchase (and debt) and the thrill of a possible *Good deal* by MGMT is now long gone before it even begun. Nice job. MGMT have been salivating to do an acquisition for over a year and telegraphed their such desire to the market and yet here we are, 10% LOWER than last year, even after beating and raising guidance all this year. Pitiful.

insiderbuyingselling Posted - 2 months ago

$ANIP new insider selling: 250 shares. http://insiderbuyingselling.com/?t=ANIP

DonCorleone77 Posted - 2 months ago

$ANIP $ALIM ANI Pharmaceuticals completes acquisition of Alimera Sciences ANI Pharmaceuticals (ANIP) announced the completion of its previously announced acquisition of Alimera Sciences (ALIM). ANI continues to expect high single-digit to low double-digit accretion in 2025 adjusted non-GAAP EPS with substantial accretion thereafter. The transaction is anticipated to deliver an additional $35 - $38 million in 2025 adjusted non-GAAP EBITDA inclusive of approximately $10 million in identified cost synergies with additional EBITDA contribution expected from accelerated growth of Cortrophin Gel within ophthalmology. ANI is maintaining its 2024 guidance for the standalone Company based on continued momentum across Cortrophin Gel and Generics and plans to provide 2024 guidance for the combined Company by no later than the Company's third quarter earnings call. Under the terms of the merger agreement, ANI acquired all of the outstanding shares of Alimera for $5.50 per share. The Company also repaid $72.5 million of Alimera debt. Alimera investors received one non-tradable contingent value right representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027. ANI recently completed an offering of $316.25 million aggregate principal amount of 2.25% convertible senior notes due September 1, 2029. The Company utilized a majority of the net proceeds as well as cash from its balance sheet to repay in full its existing senior secured term loan facility. The initial conversion price of the convertible notes is $74.11 per share. Concurrent with the convertible offering, the Company used $40.6 million of the net proceeds to enter into capped call transactions. The cap price of the capped call transactions is initially $114.02 per share, which represents a premium of 100% over the last reported sale price of the Company's common stock on August 7, 2024. The capped call transactions are expected generally to reduce the potential dilution to ANI's common stock upon any conversion of the notes up to the cap price of $114.02. To fund the acquisition of Alimera, ANI entered into a new senior secured credit agreement consisting of a $325 million delayed draw term loan facility and $75 million revolving credit facility. On September 16, 2024 the Company drew the full $325 million term loan; the $75 million revolving credit facility remains un-drawn. The Company expects these capital structure changes to reduce interest expense by approximately $39 million on an annualized basis as compared to estimated interest expense that would have been incurred if the new principal amount of debt was subject to rates that would have applied under the previous debt capital structure.

Stock_Titan Posted - 2 months ago

$ANIP ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences https://www.stocktitan.net/news/ANIP/ani-pharmaceuticals-inc-completes-acquisition-of-alimera-u6e94uw3mciy.html

Stock_Titan Posted - 2 months ago

$ANIP ANI Pharmaceuticals Launches Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution https://www.stocktitan.net/news/ANIP/ani-pharmaceuticals-launches-promethazine-hydrochloride-and-6zbq79pifzn4.html

MarkItUpABuck Posted - 2 months ago

$ANIP Management at Ani needs to go. They have zero regard for shareholders.

DonCorleone77 Posted - 2 months ago

$ANIP $ALIM ANI Pharmaceuticals, Alimera Sciences merger to close on September 16 ANI Pharmaceuticals (ANIP) and Alimera Sciences (ALIM) jointly announced that they have scheduled the closing of their transaction pursuant to the companies' previously announced Merger Agreement for before the market opens on Monday, September 16.

Stock_Titan Posted - 2 months ago

$ANIP ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger https://www.stocktitan.net/news/ANIP/ani-pharmaceuticals-and-alimera-sciences-announce-closing-date-of-9p2dqmrte7jp.html

Dy2ski Posted - 2 months ago

$ANIP What utter incompetence by Management and the BOD! Perhaps, they realized at the last second that they were grossly overpaying for Alimera the same way they overpayed for Novitium?! Either way, they look like total clowns and they've now ruined any good will with the Market and what should have been a year TO FINALLY REWARD loyal shareholders is completley unraveling. Unreal.